Mazelle Torres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mazelle Torres has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Jed Noel Ong
MakatiMed Institute of Neurological, Neurosurgical and Behavioral Sciences (M.I.N.D.S.), Makati Medical Center, Makati City, Philippines
1 shared publication - Jerickson Abbie Flores
Jose R. Reyes Memorial Medical Center, Philippines
1 shared publication - Joseree-Ann Catindig Dela Rosa
Jose R. Reyes Memorial Medical Center, Philippines
1 shared publication - Melmar Cerilo Folloso
Memory, Ageing and Cognition Centre (MACC), Department of Psychological Medicine, National University Hospital, Singapore, Singapore
1 shared publication - Stephen Lowell Ciocon
Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 23 May 2022
- Published by FapUNIFESP (SciELO) in Dementia & Neuropsychologia
- Vol. 16 (3) , 270-275
Therapeutic role of memantine for the prevention of cognitive decline in cancer patients with brain metastasis receiving whole-brain radiotherapy: a narrative review
Brain metastases are the most common central nervous system tumors. The mainstay treatment for this tumor in low to middle income countries is whole brain radiation therapy. Irreversible cognitive decline is associated with the use of whole brain radiotherapy. Several pharmacologic and nonpharmacologic options have been employed in studies focusing on the prevention of cognitive decline following whole-brain radiation therapy. Memantine use has been shown to provide some benefit in reducing the rate of decline in cognitive function and time to cognitive failure. The objective of this review article is to provide a summary on available primary literature on the therapeutic role of memantine for the prevention of cognitive decline in cancer patients with brain metastasis receiving whole brain radiotherapy.
- 23 May 2022
- Published by FapUNIFESP (SciELO) in Dementia & Neuropsychologia
- Vol. 16 (3) , 270-275
Open AccessTherapeutic role of memantine for the prevention of cognitive decline in cancer patients with brain metastasis receiving whole-brain radiotherapy: a narrative review
Brain metastases are the most common central nervous system tumors. The mainstay treatment for this tumor in low to middle income countries is whole brain radiation therapy. Irreversible cognitive decline is associated with the use of whole brain radiotherapy. Several pharmacologic and nonpharmacologic options have been employed in studies focusing on the prevention of cognitive decline following whole-brain radiation therapy. Memantine use has been shown to provide some benefit in reducing the rate of decline in cognitive function and time to cognitive failure. The objective of this review article is to provide a summary on available primary literature on the therapeutic role of memantine for the prevention of cognitive decline in cancer patients with brain metastasis receiving whole brain radiotherapy.